Strides enters into sub-licensing agreement with MPP

26 Mar 2022 , 01:33 AM

Strides Pharma Science announced a sub-license agreement with Medicines Patent Pool MPP to commercialize a generic version of Pfizers COVID-19 oral treatment in 95 low and middle-income markets Developed by Pfizer the treatment is a SARS-CoV-2 main protease inhibitor oral antiviral therapy The drug consists of nirmatrelvir tablets which are co-packaged and co-administered with ritonavir tablets The product has been authorized as a Covid-19 oral therapy for emergency use in the US and many other countries both amongst high-risk adults and high-risk pediatric patients Branded as Kovidax Strides generic version of the Pfizer oral treatment will be launched in 95 markets as part of the sub-licensing agreement with MPP The product will be manufactured at Strides flagship facility in Bengaluru and the Company has already secured its Active Pharmaceutical Ingredients API supplies through a preferred partnership arrangement